Tenofovir exalidex - ContraVir Pharmaceuticals

Drug Profile

Tenofovir exalidex - ContraVir Pharmaceuticals

Alternative Names: CMX-157; HDP-Tenofovir; Hexadecyloxypropyl-tenofovir; lipid conjugate TFV(tenofovir); Lipid conjugate YTFV; TXL™

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chimerix
  • Developer Chimerix; ContraVir Pharmaceuticals
  • Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis B
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis B
  • Suspended HIV infections

Most Recent Events

  • 22 Feb 2018 Tenofovir exalidex receives Orphan Drug status for Hepatitis B (In infants, In children) in USA
  • 12 Feb 2018 The US FDA agrees to allow ContraVir Pharmaceuticals to utilise the 505(b) regulatory pathway to develop and approve tenofovir for Hepatitis B (93364)
  • 06 Feb 2018 Adverse events and pharmacokinetics data from a phase I trial in Hepatitis B treatment (In volunteers) released by ContraVir Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top